Thelansis

Surgical Site Infections (SSIs) Market Outlook Thelansis’s “Surgical Site Infections (SSIs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Surgical Site Infections (SSIs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impac...

Surgical Site Infections (SSIs) Market Outlook Thelansis’s “Surgical Site Infections (SSIs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Surgical Site Infections (SSIs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Surgical Site Infections (SSIs) Overview Surgical Site Infections (SSIs) are a devastating and common complication of hospitalization, occurring in 2% to 5% of patients undergoing surgery in the United States. SSIs lead to increased duration of hospitalization, cost, and risk of death. Each SSI leads to more than one week of additional postoperative hospital days. Most SSIs that do not involve implants are diag...

  Surgical Site Infections (SSIs) are a devastating and common complication of hospitalization, occurring in 2% to 5% of patients undergoing surgery in the United States. SSIs lead to increased duration of hospitalization, cost, and risk of death. Each SSI leads to more than one week of additional postoperative hospital days. Most SSIs that do not involve implants are diagnosed within three weeks of surgery. SSIs are classified as either incisional or organ/ space. Incisional SSIs are further classified into superficial or deep. Organ/space SSIs include infections in tissue deep to the fascia that was opened or manipulated during surgery. For all classifications, the infection can occur within 30 days after the operation if no implant was placed or within 90 days if an implant was placed and the infection is related to the incision. SSI will occur due to a complex relationship between microbial characteristics, host characteristics, and wound elements.   In the USA, ~200,0...